.

BioPharmaceutical Business Intelligence

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

US Department of Justice
McKinsey
Healthtrust
Fish and Richardson
Deloitte
Colorcon
Dow
Julphar
Accenture
Johnson and Johnson

Generated: February 18, 2018

DrugPatentWatch Database Preview

Patents Expiring in April 2025

« Back to Dashboard

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
AcordaAMPYRAdalfampridineTABLET, EXTENDED RELEASE;ORAL022250-001Jan 22, 2010ABRXYesYes➤ Try a Free Trial➤ Try a Free TrialIMPROVEMENT OF WALKING IN PATIENTS WITH MULTIPLE SCLEROSIS (MS)
Sanofi Aventis UsAPIDRA SOLOSTARinsulin glulisine recombinantINJECTABLE;SUBCUTANEOUS021629-003Feb 24, 2009RXYesNo➤ Try a Free Trial➤ Try a Free TrialY
Sanofi Us ServicesTOUJEO SOLOSTARinsulin glargine recombinantSOLUTION;SUBCUTANEOUS206538-001Feb 25, 2015RXYesYes➤ Try a Free Trial➤ Try a Free TrialY
Sanofi Aventis UsLANTUS SOLOSTARinsulin glargine recombinantINJECTABLE;INJECTION021081-002Apr 27, 2007RXYesYes➤ Try a Free Trial➤ Try a Free TrialY
Sanofi-aventis UsSOLIQUA 100/33insulin glargine; lixisenatideSOLUTION;SUBCUTANEOUS208673-001Nov 21, 2016RXYesYes➤ Try a Free Trial➤ Try a Free TrialY
Astrazeneca AbFARXIGAdapagliflozin propanediolTABLET;ORAL202293-002Jan 8, 2014RXYesYes➤ Try a Free Trial➤ Try a Free TrialYTREATMENT OF TYPE 2 DIABETES MELLITUS IN COMBINATION WITH EXENATIDE
Astrazeneca AbBYDUREON BCISEexenatideSUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS209210-001Oct 20, 2017RXYesYes➤ Try a Free Trial➤ Try a Free TrialYTREATMENT OF TYPE 2 DIABETES
Astrazeneca AbBYDUREON BCISEexenatideSUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS209210-001Oct 20, 2017RXYesYes➤ Try a Free Trial➤ Try a Free TrialYMETHOD FOR TREATING TYPE 2 DIABETES USING A SUSTAINED-RELEASE COMPOSITION CONTAINING EXENATIDE
Astrazeneca AbBYDUREON BCISEexenatideSUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS209210-001Oct 20, 2017RXYesYes➤ Try a Free Trial➤ Try a Free TrialYTREATMENT OF TYPE 2 DIABETES
Astrazeneca AbBYDUREON PENexenatide syntheticFOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS022200-002Feb 28, 2014RXYesYes➤ Try a Free Trial➤ Try a Free TrialYTREATMENT OF TYPE 2 DIABETES
This preview shows a limited number of results
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Cipla
Express Scripts
Fish and Richardson
Moodys
Julphar
Colorcon
US Department of Justice
Chinese Patent Office
Chubb

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2018 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot